2020年8月, 河西学院附属张掖人民医院 在Cancer management and research(IF 2.5000/ 4区)上在线发表了一篇论文。在 发表4年后 ,因 图片组内重复 在pubpeer上被读者质疑。 论文题为 ...
Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.
《Molecular Neurobiology》:GDF11 Regulates M1 and M2 Polarization of BV2 Microglial Cells via p38 MAPK Signaling Pathway ...
Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...
Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in ...